Integer Holdings Corporation (NYSE:ITGR) Receives $98.71 Average Target Price from Analysts

Integer Holdings Corporation (NYSE:ITGR) has received an average rating of “Hold” from the eleven analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $98.7143.

A number of analysts recently commented on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Integer in a research report on Thursday, June 18th. Piper Sandler restated an “overweight” rating and set a $97.00 target price (up from $87.00) on shares of Integer in a research report on Friday, May 1st. Citigroup raised their target price on shares of Integer from $89.00 to $92.00 and gave the company a “neutral” rating in a research note on Thursday, May 28th. Finally, Zacks Research downgraded shares of Integer from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th.

Integer Trading Down 0.8%

NYSE:ITGR traded down $0.71 during trading hours on Tuesday, hitting $92.69. 131,192 shares of the stock were exchanged, compared to its average volume of 662,674. The company has a market capitalization of $3.15 billion, a P/E ratio of 23.12, a price-to-earnings-growth ratio of 2.27 and a beta of 0.64. The company has a quick ratio of 2.38, a current ratio of 3.75 and a debt-to-equity ratio of 0.77. The company’s 50 day moving average is $90.09 and its two-hundred day moving average is $86.54. Integer has a twelve month low of $62.00 and a twelve month high of $122.99.

Integer (NYSE:ITGR) last released its earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 EPS for the quarter, missing the consensus estimate of $1.21 by ($0.01). The firm had revenue of $439.58 million during the quarter, compared to analyst estimates of $426.48 million. Integer had a net margin of 7.64% and a return on equity of 12.83%. The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the business posted $1.31 earnings per share. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. On average, sell-side analysts anticipate that Integer will post 6.04 earnings per share for the current fiscal year.

Institutional Trading of Integer

Institutional investors and hedge funds have recently made changes to their positions in the business. Tudor Investment Corp ET AL boosted its position in shares of Integer by 50,787.5% in the 3rd quarter. Tudor Investment Corp ET AL now owns 29,500,000 shares of the medical equipment provider’s stock worth $28,606,000 after purchasing an additional 29,442,029 shares during the last quarter. Irenic Capital Management LP bought a new position in Integer during the fourth quarter worth about $99,109,000. Alliancebernstein L.P. raised its position in shares of Integer by 885.1% in the 2nd quarter. Alliancebernstein L.P. now owns 1,106,091 shares of the medical equipment provider’s stock valued at $136,016,000 after acquiring an additional 993,810 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Integer by 1,141.6% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 819,046 shares of the medical equipment provider’s stock worth $72,076,000 after acquiring an additional 753,081 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Integer by 3,350.2% during the fourth quarter. Millennium Management LLC now owns 677,108 shares of the medical equipment provider’s stock valued at $53,106,000 after purchasing an additional 657,483 shares during the period. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.